Navigation Links
Sigma-Aldrich Releases WTA2, a Transplex Whole Transcriptome Amplification Technology for Degraded RNA Samples
Date:10/27/2008

WTA2 Kits Offer Rapid, Robust Amplification of Partially Degraded RNA

ST. LOUIS, Oct. 28 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of its TransPlex(R) Whole Transcriptome Amplification (WTA2) technology (http://www.sigma.com/wta). TransPlex technology is believed to be the fastest, most sensitive and robust method available for amplifying total RNA from a variety of sample tissue sources such as animals, plants, and microorganisms. Optimized for formalin-fixed and paraffin-embedded tissue samples, WTA2 is the second addition to the patent-pending suite of WTA products designed to study RNA in vitro.

"Sigma-Aldrich is committed to bringing best-in-class technologies to the genomic research community," said Helge Bastian, Vice President of Marketing for Sigma-Aldrich's Research Biotech Business Unit. "The TransPlex(R) Whole Transcriptome Amplification product line adds an important tool for researchers who work with limited quantity and quality of RNA samples."

The TransPlex WTA technology creates a cDNA library from total RNA template and then amplifies the cDNA library in a single PCR reaction. The TransPlex reagents and protocols, optimized to ensure clonal and stochastic amplification of all expressed genes and exons, allow RNA samples to be amplified 1,000-10,000 fold in less than four hours. Sigma-Aldrich's WTA2 technology is highly robust, designed for use with RNA is partially degraded, as in formalin-fixed paraffin-embedded tissue derived from tumor samples.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 8,000 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.

About Rubicon Genomics: Rubicon, located in Ann Arbor, MI, commercializes its OmniPlex(R) and EnzyPlex(R) families of technologies for diagnostics, research, and service. Rubicon has partnered with large diagnostic and pharmaceutical companies to develop proprietary MethylPlex(R) diagnostic and predictive tests for methylated DNA biomarkers discovered for prostate, bladder, breast, and lung cancer. Rubicon will continue to offer commercial services for whole genome and whole transcriptome amplification from DNA, serum, and formalin-fixed sections. OmniPlex(R), EnzyPlex(R), GenomePlex(R), MethylPlex(R), and TransPlex(R) are trademarks of Rubicon Genomics. More information can be found at http://www.rubicongenomics.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):